A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities

Trial Profile

A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Aleglitazar (Primary)
  • Indications Cardiovascular disorders; Prediabetic-state; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms AlePrevent
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2015 Results published in the American Heart Journal.
    • 10 Jul 2013 Status changed from recruiting to discontinued, according to a Roche media release.
    • 23 May 2013 Planned End Date changed from 1 Jul 2018 to 1 Feb 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top